Company intelligence / Profile preview
Taejoon Pharmaceutical Co., Ltd.
Yongsan-gu, Seoul, South Koreataejoon.co.kr ↗
- Ownership
- Private
- Employees
- ~51
- Development stage
- Other
01
Overview
Taejoon has multiple commercialized products in ophthalmology and radiology globally. Their R&D pipeline includes preclinical to Phase 3 assets targeting eye and GI diseases. Notably, their anti-VEGFR2 antibody program aims to address unmet needs in wet AMD patients unresponsive to current anti-VEGF therapies. They are also active in developing improved formulations and new indications for existing drugs[1][5][8].
- Therapeutic areas
- OtherOphthalmologyGastroenterology
- Modalities
- Small moleculesmonoclonal antibodiesmolecular gluescontrast agents[5][10]
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
03
Partnerships
License contract with original developer of TJO–054 monoclonal antibody [8]
Beyond the preview
Go deeper on Taejoon Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taejoon Pharmaceutical Co., Ltd..